[HTML][HTML] Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer

Y Kiyohara, N Yamazaki, A Kishi - Journal of the American Academy of …, 2013 - Elsevier
Skin toxicities are the most common side effects associated with the epidermal growth factor
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …

Drug-induced hepatotoxicity in cancer patients-implication for treatment

B Vincenzi, G Armento, M Spalato Ceruso… - Expert opinion on …, 2016 - Taylor & Francis
Introduction: All anticancer drugs can cause idiosyncratic liver injury. Therefore,
hepatoprotective agents assume particular importance to preserve liver function. Hepatic …

[HTML][HTML] A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously …

H Yoshioka, K Azuma, N Yamamoto, T Takahashi… - Annals of …, 2015 - Elsevier
Background A previous randomized phase II study demonstrated that the addition of a c-Met
inhibitor tivantinib to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor …

[HTML][HTML] Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer

T Kato, N Masuda, Y Nakanishi, M Takahashi, T Hida… - Lung cancer, 2017 - Elsevier
Objectives Drug-induced interstitial lung disease (ILD) is often associated with high
mortality; however it is difficult to predict and manage. we examined the clinical findings and …

Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta …

CH Suh, HS Park, KW Kim, J Pyo, H Hatabu, M Nishino - Lung cancer, 2018 - Elsevier
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …

[HTML][HTML] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …

K Goto, M Nishio, N Yamamoto, K Chikamori, T Hida… - Lung Cancer, 2013 - Elsevier
Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …

Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis

CJ Ensslin, AC Rosen, S Wu, ME Lacouture - Journal of the American …, 2013 - Elsevier
Background Pruritus has been anecdotally described in association with targeted cancer
therapies. The risk of pruritus has not been systematically ascertained. Objective A …

Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas

RR Shah - Drug safety, 2016 - Springer
Since the approval of the first molecularly targeted tyrosine kinase inhibitor (TKI), imatinib, in
2001, TKIs have heralded a new era in the treatment of many cancers. Among their …

Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP

Y Kobayashi, Y Komatsu, S Yuki, H Fukushima… - Future …, 2015 - Future Medicine
Aim: We planned a randomized, open-label trial to evaluate differences between pre-
emptive and reactive skin treatment for panitumumab (Pmab)-associated skin toxicities in …

Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non‐small‐cell lung cancer

A Gemma, S Kudoh, M Ando, Y Ohe… - Cancer …, 2014 - Wiley Online Library
Interstitial lung disease (ILD) occurrence and risk factors were investigated in the Japanese
non‐small‐cell lung cancer, post‐marketing, large‐scale surveillance study, POLARSTAR …